drugset / Trial / NCT02386007
Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Gastric Inflammation Patients
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to find optimum dosage of DW-3101 by evaluating efficacy and safety of each dosage group in Korean patients with acute and chronic gastric inflammation.
Timeline
- Start
- —
- Primary completion
- 2017-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DW-3101 | Unknown | 150 mg | — |
| Subject | DW-3101 | Unknown | 300 mg | — |
| Subject | DW-3101 | Unknown | 600 mg | — |